TKI Induction Followed by a Randomized Comparison between Nivolumab or TKI Continuation in Renal Cell Carcinoma (NiVOSWiTCH)

Grunwald, V; Grullich, C; Ivanyi, P; Wirth, M; Staib, P; Schostak, M; Dargatz, P; Muller, L; Metz, M; Bergmann, L; Steiner, T; Welslau, M; Lorch, A; Schutt, P; Rafiyan, MR; Hellmis, E; Hinke, A; Manz, M; Meiler, J; Kretz, T; Loidl, W; Florcken, A

ONCOLOGY RESEARCH AND TREATMENT, 2020; 43 (): 78